Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
59
COGT Quote, Financials, Valuation and Earnings
Last price:
$39.75
Seasonality move
:
-9.39%
Day range:
$39.60 - $40.40
52-week range:
$3.72 - $43.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
55.99x
P/B ratio:
31.35x
Volume:
581K
Avg. volume:
3.2M
1-year change:
405.47%
Market cap:
$6.1B
Revenue:
--
EPS (TTM):
-$2.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
-- | -$0.52 | -- | -16.97% | $49.18 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
ANAB
AnaptysBio, Inc.
|
$21.8M | -$1.25 | 102.4% | -12.82% | $65.09 |
|
EDIT
Editas Medicine, Inc.
|
$4.9M | -$0.38 | -72.38% | -61.06% | $5.13 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$130.5M | -$1.05 | -32.42% | -80.04% | $87.99 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
$39.73 | $49.18 | $6.1B | -- | $0.00 | 0% | 55.99x |
|
ADMA
ADMA Biologics, Inc.
|
$19.53 | $25.67 | $4.6B | 22.93x | $0.00 | 0% | 9.83x |
|
ANAB
AnaptysBio, Inc.
|
$50.09 | $65.09 | $1.4B | -- | $0.00 | 0% | 8.79x |
|
EDIT
Editas Medicine, Inc.
|
$2.21 | $5.13 | $215.7M | -- | $0.00 | 0% | 4.05x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$80.33 | $87.99 | $13B | -- | $0.00 | 0% | 13.68x |
|
PFE
Pfizer Inc.
|
$24.88 | $28.62 | $141.5B | 14.50x | $0.43 | 6.91% | 2.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
16.68% | 3.554 | 2.86% | 6.28x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ANAB
AnaptysBio, Inc.
|
109.28% | 2.106 | 41.03% | 8.52x |
|
EDIT
Editas Medicine, Inc.
|
85.41% | 3.856 | 24.32% | 2.81x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.444 | 19.43% | 2.51x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
-$1.1M | -$83.4M | -103.58% | -117.99% | -- | -$64.4M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ANAB
AnaptysBio, Inc.
|
$75.7M | $34.7M | -22.38% | -367.62% | 45.47% | -$27.4M |
|
EDIT
Editas Medicine, Inc.
|
$6.8M | -$24.5M | -149.99% | -246.73% | -325.44% | -$31.3M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Cogent Biosciences, Inc. vs. Competitors
-
Which has Higher Returns COGT or ADMA?
ADMA Biologics, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of 27.14%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About COGT or ADMA?
Cogent Biosciences, Inc. has a consensus price target of $49.18, signalling upside risk potential of 23.79%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 31.69%. Given that ADMA Biologics, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.8 2 0 ADMAADMA Biologics, Inc.3 0 0 -
Is COGT or ADMA More Risky?
Cogent Biosciences, Inc. has a beta of 0.505, which suggesting that the stock is 49.519% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock COGT or ADMA?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or ADMA?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Cogent Biosciences, Inc.'s net income of -$80.9M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 22.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 9.83x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M ADMAADMA Biologics, Inc.9.83x 22.93x $134.2M $36.4M
-
Which has Higher Returns COGT or ANAB?
AnaptysBio, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of 19.8%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat AnaptysBio, Inc.'s return on equity of -367.62%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M ANABAnaptysBio, Inc.99.2% $0.52 $317M -
What do Analysts Say About COGT or ANAB?
Cogent Biosciences, Inc. has a consensus price target of $49.18, signalling upside risk potential of 23.79%. On the other hand AnaptysBio, Inc. has an analysts' consensus of $65.09 which suggests that it could grow by 30.08%. Given that AnaptysBio, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe AnaptysBio, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.8 2 0 ANABAnaptysBio, Inc.8 1 0 -
Is COGT or ANAB More Risky?
Cogent Biosciences, Inc. has a beta of 0.505, which suggesting that the stock is 49.519% less volatile than S&P 500. In comparison AnaptysBio, Inc. has a beta of 0.286, suggesting its less volatile than the S&P 500 by 71.412%.
-
Which is a Better Dividend Stock COGT or ANAB?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnaptysBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. AnaptysBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or ANAB?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than AnaptysBio, Inc. quarterly revenues of $76.3M. Cogent Biosciences, Inc.'s net income of -$80.9M is lower than AnaptysBio, Inc.'s net income of $15.1M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while AnaptysBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 8.79x for AnaptysBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M ANABAnaptysBio, Inc.8.79x -- $76.3M $15.1M
-
Which has Higher Returns COGT or EDIT?
Editas Medicine, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -332.98%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Editas Medicine, Inc.'s return on equity of -246.73%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M EDITEditas Medicine, Inc.90.44% -$0.28 $92.2M -
What do Analysts Say About COGT or EDIT?
Cogent Biosciences, Inc. has a consensus price target of $49.18, signalling upside risk potential of 23.79%. On the other hand Editas Medicine, Inc. has an analysts' consensus of $5.13 which suggests that it could grow by 131.9%. Given that Editas Medicine, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Editas Medicine, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.8 2 0 EDITEditas Medicine, Inc.6 7 0 -
Is COGT or EDIT More Risky?
Cogent Biosciences, Inc. has a beta of 0.505, which suggesting that the stock is 49.519% less volatile than S&P 500. In comparison Editas Medicine, Inc. has a beta of 2.441, suggesting its more volatile than the S&P 500 by 144.07%.
-
Which is a Better Dividend Stock COGT or EDIT?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Editas Medicine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or EDIT?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Editas Medicine, Inc. quarterly revenues of $7.5M. Cogent Biosciences, Inc.'s net income of -$80.9M is lower than Editas Medicine, Inc.'s net income of -$25.1M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Editas Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 4.05x for Editas Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M EDITEditas Medicine, Inc.4.05x -- $7.5M -$25.1M
-
Which has Higher Returns COGT or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -82.06%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About COGT or IONS?
Cogent Biosciences, Inc. has a consensus price target of $49.18, signalling upside risk potential of 23.79%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 9.54%. Given that Cogent Biosciences, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.8 2 0 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is COGT or IONS More Risky?
Cogent Biosciences, Inc. has a beta of 0.505, which suggesting that the stock is 49.519% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.
-
Which is a Better Dividend Stock COGT or IONS?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or IONS?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Cogent Biosciences, Inc.'s net income of -$80.9M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 13.68x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M IONSIonis Pharmaceuticals, Inc.13.68x -- $156.7M -$128.6M
-
Which has Higher Returns COGT or PFE?
Pfizer Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of 21.32%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About COGT or PFE?
Cogent Biosciences, Inc. has a consensus price target of $49.18, signalling upside risk potential of 23.79%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 15.04%. Given that Cogent Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.8 2 0 PFEPfizer Inc.7 15 1 -
Is COGT or PFE More Risky?
Cogent Biosciences, Inc. has a beta of 0.505, which suggesting that the stock is 49.519% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock COGT or PFE?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or PFE?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Cogent Biosciences, Inc.'s net income of -$80.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 2.26x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M PFEPfizer Inc.2.26x 14.50x $16.7B $3.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
